Back to Research Feed

Life sciences · Observational Study

The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

ClinicalTrials.gov · September 28, 2026

Why this matters to you Expert discussion

AI Summary

No summary has been generated for this record yet. What follows is drawn from its source metadata only.

What was studied

Observational Study.

Key findings

No findings were extractable from the material analysed.

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

not graded

The material analysed did not support a judgement on this dimension.

Directness

not graded

The material analysed did not support a judgement on this dimension.

Consistency

not graded

The material analysed did not support a judgement on this dimension.

Risk of bias

not graded

The material analysed did not support a judgement on this dimension.

Sample adequacy

not graded

The material analysed did not support a judgement on this dimension.

This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.

What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07039474). This is a study registration, not published results. Lead sponsor: Peking University First Hospital. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 120 participants (ESTIMATED). Conditions: Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Lymphoma. Interventions: DRUG: 18F-G1. Primary outcome measures: Number of participants with 18F-G1-related adverse events (AEs). , 3 days after the injection of 18F-G1; Tumor uptake of 18F-G1 , 40-60 minutes after the injection of 18F-G1; Liver uptake of 18F-G1 , 40-60 minutes after the injection of 18F-G1; Lung uptake of 18F-G1 , 40-60 minutes after the injection of 18F-G1; Kidney uptake of 18F-G1 , 40-60 minutes after the injection of 18F-G1; the granzyme B specificity of 18F-G1 , 3 years; Assessing the early predictive value of 18F-G1 PET/CT for immunotherapy response. , 6 months. Brief summary: The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy

Sign in to save Open original source